$5.52
1.85% yesterday
NYSE, Jun 12, 10:04 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Stock price

$5.52
+0.92 20.00% 1M
+1.11 25.17% 6M
+1.74 46.03% YTD
+3.81 222.81% 1Y
-12.55 69.45% 5Y
-12.55 69.45% 10Y
-12.55 69.45% 20Y
NYSE, Closing price Thu, Jun 12 2025
+0.10 1.85%
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Key metrics

Market capitalization $492.06m
Enterprise Value $287.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -472.11
P/B ratio (TTM) P/B ratio 2.44
Revenue growth (TTM) Revenue growth -100.15%
Revenue (TTM) Revenue $-610.00k
EBIT (operating result TTM) EBIT $-230.40m
Free Cash Flow (TTM) Free Cash Flow $-243.29m
Cash position $204.07m
EPS (TTM) EPS $-2.55
P/E forward negative
Short interest 5.11%
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Amylyx Pharmaceuticals forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
86%
Hold
14%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
-0.61 -0.61
100% 100%
100%
- Direct Costs 8.23 8.23
81% 81%
-
-8.83 -8.83
102% 102%
-
- Selling and Administrative Expenses 72 72
64% 64%
-
- Research and Development Expense 90 90
36% 36%
-
-230 -230
1,949% 1,949%
-
- Depreciation and Amortization 0.75 0.75
38% 38%
-
EBIT (Operating Income) EBIT -230 -230
2,153% 2,153%
-
Net Profit -219 -219
208% 208%
-

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
GlobeNewsWire
2 days ago
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Neutral
Business Wire
10 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis.
Neutral
Business Wire
23 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences.
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 384
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today